Milciclib (Standard)
Milciclib (Standard) is the analytical standard of Milciclib. This product is intended for research and analytical applications. Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 802539-81-7
- 分子式: C25H32N8O
- 分子量:460.57
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
化学情報
- 純度とドキュメンテーション
-
Help & FAQs
-
HY-10424
MilciclibCDK/TRK Inhibitor -
HY-10005
FlavopiridolCDK Inhibitor -
HY-10492
DinaciclibCDK2/5/9 Inhibitor -
HY-12302
KenpaulloneCDK1/GSK-3β Inhibitor -
HY-12529
Ro-3306CDK1 Inhibitor -
HY-16297A
AbemaciclibCDK4/6 Inhibitor -
HY-15777
RibociclibCDK4/6 Inhibitor -
HY-18299A
Purvalanol ACDK Inhibitor -
HY-11001
PHA-793887Cyclin-dependent Kinase Inhibitor -
HY-30237
(R)-RoscovitineCDKs Inhibitor -
HY-10008
SNS-032CDK Inhibitor -
HY-10006
Flavopiridol HydrochlorideCDK Inhibitor
Product Information
説明
アプリケーション
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
化学情報
-
CAS 番号 802539-81-7
-
分子量 460.57
-
分子式 C25H32N8O
-
SMILES
O=C(NC)C1=NN(C2=C1C(C)(CC3=CN=C(N=C23)NC4=CC=C(C=C4)N5CCN(CC5)C)C)C
-
別名
PHA-848125 (Standard)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, Del Bufalo D, Desideri M, Bonmassar E, Pfeffer U, D'Atri S. Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochem Pharmacol. 2012 Sep 1;84(5):598-611. [Content Brief]
[2]. Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther. 2010 Aug;9(8):2243-54. [Content Brief]
[3]. Degrassi A, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther. 2010 Mar;9(3):673-81. [Content Brief]
[4]. Brasca, M.G., et al. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J. Med. Chem. 52(16), 5152-5163 (2009). [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Milciclib (Standard) 関連分類
HY-10424R 関連分類
Powered by Bioz